WHCCAMP
This article was originally published in The Tan Sheet
Executive Summary
FDA should initiate a review process much like its ongoing OTC monograph review to evaluate botanicals and appoint a "dietary supplement ombudsman," American Herbal Products Association asserts in recent letter to White House Commission for Complementary & Alternative Medicine. AHPA maintains agency's August 2000 "Botanicals Drug Guidance" does not sufficiently address marketing botanicals with a long history of use as nonprescription drugs. WHCCAMP also should recommend FDA employ "responsible advocate" for supplement industry in its report to President. Interim report was scheduled for July 16, but has yet to be released (1"The Tan Sheet" July 9, p. 8)